We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Metabolism Measurements Predict Progress of Alzheimer’s disease

By LabMedica International staff writers
Posted on 01 Jan 2013
Metabolic studies could help cure Alzheimer’s disease (AD); measuring metabolism can predict the progress of the disease.

Before any symptoms of AD appear, metabolic processes start to change in the brain, according to an Israeli team from the Tel Aviv's Sackler School of Medicine (Tel Aviv, Israel) and TAU Blavatnik School of Computer Science (Tel Aviv, Israel). More...
These scientists developed predictor models that use metabolic information to pinpoint the progression of Alzheimer's. These models were 90% accurate in predicting the stage of the disease.

To discover the connection between metabolism, brain functioning, and Alzheimer's disease, the researchers used data collected from the hippocampus region of the brain. Controlling memory and learning, this region of the brain is damaged as Alzheimer's progresses.

The team built a predictive model based on the number of metabolic genes found in the neurons and surrounding tissue, which relates abnormalities in these genes to the progression of the disease. Out of almost 1,500 genes, the researchers were able to select 50 genes that were the most predictive of Alzheimer's, said Dr. Shiri Stempler at the Tel Aviv University Sackler School of Medicine, noting that in Alzheimer's patients these genes either are over or under expressed.

Findings were compared from these 50 genes among Alzheimer's patients, healthy patients, and primates (including chimpanzees and rhesus monkeys) and discovered that in all except the Alzheimer's group, the number of specific genes was tightly limited, with little difference in their number between individuals among each of the species. This implied that these genes are significant to normal brain functioning, and their strict regulation in healthy patients is compromised by Alzheimer's disease.

Whether metabolic changes are a cause of the disease or merely a symptom remains a topic for future study. But the discovery of this connection is encouraging. "The correlation between metabolic gene expression and cognitive score in Alzheimer's patients is even higher than the correlation we see in medical literature between beta amyloid plaques–found in deposits in the brains of Alzheimer's patients–and cognitive score, pointing to a strong association between cognitive decline and an altered metabolism," Dr Stempler said.

Now the team will try to identify biomarkers in the blood that are associated with these metabolic changes. They may lead to detection and information about the disease's progression with an easy and noninvasive blood test. As their work advances, they hope to develop therapeutic strategies that are based around these alterations in the metabolic network to help Alzheimer's patients, such as medications that can reintroduce strict regulation over gene expression.

The research is the first step towards identifying biomarkers that may ensure better detection and analysis of the disease at an early stage, all with a simple blood test. It could also lead to novel therapies.

The study was reported in the journal Neurobiology of Aging.

Related Links:
Tel Aviv's Sackler School of Medicine
TAU Blavatnik School of Computer Science


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.